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Summary Evidence is accumulating for the failure of apoptosis as an important factor in the evolution of
colorectal cancer and its poor response to adjuvant therapy. The proto-oncogene bcl-2 suppresses apoptosis. Its
expression could provide an important survival advantage permitting the development of colorectal cancer. The
expression of bcl-2 and p53 was determined by immunohistochemistry in 47 samples of histologically normal
colonic mucosa, 19 adenomas and 53 adenocarcinomas. Expression of bcl-2 in colonic crypts > 5 cm from the
tumours was confined to crypt bases but was more extensive and intense in normal crypts < 5 mm from
cancers. A higher proportion of adenomas (63.2%) than carcinomas (36.5%) expressed bcl-2 (P<0.05). A
lower proportion of adenomas (31.6%) than carcinomas (62.3%) expressed p53 (P< 0.02). A total of 26.3% of
adenomas and 22% of carcinomas expressed both bcl-2 and p53. To determine whether these samples
contained cells which expressed both proteins, a dual staining technique for bcl-2 and p53 was used. Only 1/19
adenomas and 2/53 carcinomas contained cells immunopositive for both bcl-2 and p53. Moreover there was
evidence of reciprocity of expression of bcl-2 and p53 in these three double staining neoplasms. We suggest that
bcl-2 provides a survival advantage in the proliferative compartment of normal crypts and colorectal
neoplasms. However, its expression is lost during the evolution from adenoma to carcinoma, whereas p53
expression is increased, an event generally coincident with the expression of stabilised p53, which we presume
to represent the mutant form.
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Evidence is accumulating to support the hypothesis that
attenuation of apoptosis may be an important factor in the
evolution of colorectal cancer and its poor response to
chemotherapy and radiation (reviewed by Watson, 1995).
Differences in the site and incidence of apoptosis may
contribute to the 100-fold lower incidence of small intestinal
cancer relative to colorectal cancer (reviewed by Potten, 1992).
Spontaneous and radiation-induced apoptosis is more abun-
dant in the small intestine compared to the colon and has the
greatest incidence at the presumed position of stem cells within
the crypt. This protective mechanism favours immediate
deletion of stem cells with malignant mutations before the
generation of neoplastic clones. In contrast, in colonic crypts
apoptosis is not focused at the site of the stem cell population
possibly due to the expression of bcl-2 at this location (Merritt
et al., 1995), potentially permitting the development of
malignant clones (Potten, 1992; Potten et al., 1992).
bcl-2 is expressed at the base of colonic crypts at the
presumed location of stem cells whereas in small intestinal
crypts its expression is much reduced (Hockenbury et al.,
1991; Hague et al., 1994; Merritt et al., 1995; Sinicrope et al.,
1995; Bronner et al., 1995). Its expression in colonic crypts
may contribute to the relative resistance of colonic epithelial
cells to apoptosis. This proto-oncogene suppresses apoptosis
induced by a variety of stimuli including radiation and
chemotherapeutic agents used for the treatment of colorectal
cancer such as 5-fluorouracil (Fisher et al., 1993). We have
confirmed the functional importance of colonic bcl-2
expression by demonstrating higher rates of spontaneous
and radiation-induced apoptosis in the stem cell region of
colonic crypts of homozygously bcl-2 null C57BL/6 mice
compared with wild-type mice (Merritt et al., 1995). These
studies suggest that bcl-2 may be an important cell survival
factor in colorectal cancer, permitting the growth of
malignant clones and thereafter contributing to resistance to
treatment.
The relationship between bcl-2 expression and the
evolution from normal colonic epithelium to invasive cancer
is not fully understood. Initial studies have suggested that
between 90% and 100% of colorectal cancers express bcl-2
(Bronner et al., 1995; Hague et al., 1994), although a later
study found a lower proportion of colorectal cancers (55%)
were bcl-2 positive (Ofner et al., 1995). However, there is also
evidence to suggest that bcl-2 expression is lost during
evolution of colorectal cancer (Sinicrope et al., 1995). Loss of
heterozygosity of the bcl-2 gene locus on chromosome
18q21.3 occurs in 60% of colorectal cancers (Ayhan et al.,
1994). Moreover both wild-type and some p53 mutants
transcriptionally repress bcl-2 by binding to a transcriptional
silencer element in the bcl-2 promoter (Miyashita et al.,
1994a). Evidence for regulation of bcl-2 by wild-type p53 has
been found in vivo in mice (Miyashita et al., 1994b) and
cultured breast cancer cells (Haldar et al., 1994). We have
previously reported preliminary evidence for an inverse
relationship between bcl-2 and p53 expression in colorectal
adenomas and carcinomas (Merritt et al., 1995), though a
more extensive report has since suggested this inverse
relationship is confined to adenomas and does not occur in
carcinomas (Sinicrope et al., 1995). However, it remains
unclear whether individual cells express both bcl-2 and p53 or
whether tumours possess topographically distinct areas of
bcl-2 and p53 expression.
In order to resolve these questions, bcl-2 and p53
expression was determined immunohistochemically in colo-
rectal adenomas and carcinomas. We found that a high
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proportion of adenomas expressed bcl-2 protein but
expression of the protein was less frequent in carcinomas.
Using a double staining technique we have provided
evidence for a strong inverse relationship between bcl-2
and p53 expression in both colorectal adenomas and
carcinomas.
Materials and methods
Specimen collection
A total of 19 adenomas and 53 adenocarcinomas were
obtained either from surgical resection specimens immediately
after removal from the patient or by endoscopic biopsy. All
adenomas were of the tubulovillous type. In 47 of the
adenocarcinoma cases apparently normal tissue 5 cm or more
from the cancer was also obtained. Samples were graded for
Dukes' stage and histological type according to standard
criteria (Jass et al., 1986). In six adenocarcinomas Dukes'
staging was not obtainable because samples were obtained
from endoscopic biopsy and the patients did not proceed to
laparotomy. Three of the Dukes' C adenocarcinomas were
known to have distant metastases when the sample was
obtained. Specimens were either fixed in 4% neutral buffered
formalin for 24 h or snap frozen, paraffin embedded and
3,um sections cut and mounted onto slides coated with 3-
aminopropyltriethoxysilane.
Single antigen immunohistochemistry for bcl-2 or p53
As described previously (Merritt et al., 1995), serial sections
were dewaxed in fresh xylene for 10 min, rehydrated
through a graded alcohol series and then transferred into
phosphate-buffered saline (PBS). Sections were then micro-
waved at high power (Matsui, model M180TC oven) for 25
min in citrate buffer, pH 6.0, allowed to cool and were then
washed in PBS. Endogenous peroxidase activity was blocked
by incubating in 0.3% hydrogen peroxide for 15 min
followed by a PBS wash. All samples were routinely
blocked for 30 min in 1:10 normal horse serum diluted in
PBS before the addition of antibody. The antibodies
employed were as follows: a murine monoclonal IgGI
antibody (bcl-2 124) raised against human bcl-2 protein
(Dako, High Wycombe, UK), or the murine monoclonal
1801 (Ab-2) anti-human p53 antibody (Oncogene Science,
Cambridge, UK) which detects both wild-type and mutant
p53 protein. Both antibodies were diluted 1:100 and then
incubated with the sections overnight at 4°C. After a PBS
wash, the preparations were incubated with biotinylated
horse anti-mouse IgG (Vector, Peterborough, UK), diluted
1:200 in PBS for 60 min. Sections were then washed in PBS
and incubated in ABC peroxidase 'Elite' (Vector, Peterbor-
ough, UK). Peroxidase-stained sections were developed with
0.3 pigml-1 3,3' diaminobenzidine, 0.03% hydrogen peroxide
and counterstained with 1% Gill's haematoxylin solution for
30 s before dehydration, clearing and mounting in Xam
(BDH, Poole, UK). A negative control section was included
on each slide. These were processed as described above
except that the primary antibody was replaced with control
IgG1 (Dako, High Wycombe, UK) diluted 1:33 with PBS.
Dual antigen immunohistochemistry for bcl-2 and p53
Sections were prepared as described above and sections were
incubated overnight at 4°C with bcl-2 primary antibody diluted
1:100 in PBS and 0.2% Tween 20. After washing in PBS-Tween,
samples were incubated for 60 min with biotinylated horse anti-
mouse IgG diluted 1:200 in PBS. Sections were then washed in
PBS and incubated with ABC 'Elite'. After washing in PBS,
sections were developed in 3 amino-9-ethylcarbazole (AEC)
(Vector, Peterborough, UK) and washed in distilled water then
PBS. Samples were blocked for 30 min in 1:10 normal horse
Figure 1 Peroxidase staining of Bcl-2 protein in a 3 gim section of histologically normal colonic epithelium (a) more than 5 cm
away from an adenocarcinoma and (b) less than 5 mm away from an adenocarcinoma ( x 200).
serum in PBS, before the addition of the p53 primary antibody
diluted 1:100 in PBS-Tween for 60 min at room temperature.
After washing in PBS-Tween, incubation with secondary
antibody followed by ABC peroxidase 'Elite' and washing was
repeated. Sections were then developed with 0.3 jg ml-' 3,3'
diaminobenzidine (DAB), 10% nickel chloride, 0.03% hydro-
gen peroxide in PBS before washing in distilled water and
mounting in aqueous mount (Glycergel, Dako).
Methods of analysis
Staining patterns of p53 were classified into the following
categories: diffuse-more than 50% epithelial nuclei staining;
focal -focal areas within the tumour with staining of > 50%
of epithelial nuclei; scattered- nuclear staining of widely
scattered epithelial cells (Fisher et al., 1994). Tumours with
< 1% of nuclei staining positive or staining confined to the
cytoplasm excluding the nucleus were considered negative.
bcl-2 staining was classified as follows: diffuse-more than
50% of epithelial cells with cytoplasmic staining within the
tumour, focal-focal areas within the tumour with staining of
> 50% of epithelial cell cytoplasm. Intensity of bcl-2 staining
of lymphocytes was used as an internal positive control.
Sections in which lymphocytes were bcl-2 negative were
rejected and restained.
Statistical methods
Comparison of bcl-2 and p53 immunostaining in adenomas
and carcinomas was analysed by the chi-squared test. The
association of immunostaining and site within the colon,
Dukes' stage and degree of histological differentiation was
made by the chi-squared test for trend. A P-value of < 0.05
was considered significant.
Results
bcl-2 expression
Normal mucosa bcl-2 expression was confined to the base of
crypts in histologically normal colonic tissue more than 5 cm
from tumours and was localised to the cytoplasm and nuclear
membrane, confirming our previous observations (Merritt et
al., 1995) (Figure la). Expression was found in 47/47 (100%)
of samples examined. However, in histologically normal
crypts immediately adjacent (less than 5 mm) to adenocarci-
nomas or Peyer's patches, bcl-2 staining extended higher up
the crypt and was more intense than in more distant crypts
(Figure lb).
Adenomas Positive bcl-2 staining of dysplastic epithelial
cells was found in 12/19 (63.2%) of the adenomas examined.
In all cases, bcl-2 immunoreactivity was confined to the
cytoplasm and nuclear membrane (Figure 2b). A total of 4/12
(33%) bcl-2-positive adenomas had a diffuse staining pattern
throughout the tumour (Figure 2b) while 8/12 (67%) had a
focal pattern of staining. No relationship was found between
site within the colon, histological stage of differentiation and
bcl-2 immunoreactivity (Table I).
Adenocarcinomas A lower proportion of adenocarcinomas
19/52 (36.5%) (P<0.05) than adenomas contained areas of
bcl-2 immunoreactivity (Figure 2a and c). Sections in which
epithelial cells were negative for bcl-2 immunostaining were
restained. Sections were only accepted for analysis if the
lymphocytes were bcl-2 positive (see Figure 2b insert). One
carcinoma was excluded from analysis because both the
antibody and control sections were immunopositive, calling
into question the validity of the bcl-2 immunostaining in this
sample. In 3/19 (15.8%) of bcl-2-positive cases there was a
diffuse pattern of staining (Figure 2c) whereas 16/19 (84.2%)
had a focal pattern of immunoreactivity. However, even in
cases which exhibited a diffuse pattern of staining,
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heterogeneity of staining intensity was observed (Figure
3a -d). As in adenomas, staining was mainly cytoplasmic
though perinuclear staining (Figure 3b) was occasionally
observed. bcl-2 immunoreactivity was more frequent in well
differentiated than moderately or poorly differentiated
Figure 2 Peroxidase staining of bcl-2 protein in two well-
differentiated adenocarcinomas, Dukes' stage B (a) and Dukes'
stage A (c), and a tubullovillous adenoma (b). In a the epithelial
cells do not stain for bcl-2 but the lymphocytes (indicated by
arrows) are bcl-2 positive. In b and c there is diffuse cytoplasmic
staining of the cytoplasm. The inset shows bcl-2 staining of
lymphocytes from the same section ( x 300).
Table I Clinicopathological features of adenomas and Bcl-2 and
p53 immunoreactivity
Bcl-2-positive p53-positive
Feature Number of cases (%) Number of cases (%)
Immunoreactivity 12/19 (63.2%) 6/19 (31.6%)
Site of tumour
Rectum 6/9 (66.6%) 2/9 (22.2%)
Sigmoid colon 5/7 (71.4%) 4/7 (57.1%)
Descending colon 0/1 (0%) 0/1 (0%)
Proximal colon 1/2 (50%) 0/2 (0%)
_I, e S . p : r ...................................................................................... '1.4A*._-i--~:'....?"~1
bcl-2 and p53 expression in colorectal tumours
ffF AJM Watson et al
892
Table II Clinicopathological features of carcinomas and Bcl-2 and
p53 immunoreactivity
Bcl-2-positive pS3-positive
Feature Number of cases Number of cases
(%) (%)
Immunoreactivity 19/52a (36.5%) 33/53 (62.3%)
Site of tumour
Rectum 6/18 (33.3%) 10/18 (30.3%)
Sigmoid colon 6/13 (46.2%) 11/13 (84.6%)
Descending colon 3/5 (60%) 5/6 (83.3%)
Proximal colon 4/15 (26.7%) 7/16 (43.7%)
Dukes' stage
A 4/5 (80%) 3/5 (60%)
B 8/27 (29.6%) 18/27 (66.7%)
C 6/14 (42%) 9/15 (60%)
Degree of histological
differentiation
Well differentiated 8/12 (66.6%)b 10/12 (83.3%)
Moderately differentiated 9/34 (26.4%) 18/34 (52.9%)
Poorly differentiated 0/2 (0%) 1/2 (50%)
Signet ring pattern 0/1 (0%) 1/1 (100%)
Carcinoma in situ 2/4 (50%) 3/4 (75%)
aOne carcinoma was unsuitable for bcl-2 immunostaining (see text).bBcl-2 immunostaining is associated with well-differentiated adeno-
carcinomas. P=0.00754.
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Figure 3 Peroxidase staining of bcl-2 protein in a well-
differentiated adenocarcinoma, Dukes' stage B. In all sections
there is heterogeneity of strong bcl-2 staining. In b bcl-2 staining
of the perinuclear membrane is shown (arrows). c and d show
high-power images of the cytoplasmic bcl-2 staining, a and b,
x 370, c and d, x 670.
adenocarcinomas but no relationship was found between
tumour site within the colon, or Dukes' stage (Table II).
p53 expression
Normal mucosa No nuclear p53 staining of normal
epithelium was found (Figure 4). In some samples
cytoplasmic staining was observed at the apex of crypts but
the nuclei remained uniformly negative.
Adenomas A total of 6/19 (31.6%) adenomas had p53
immunopositive nuclei. Of these positive tumours, 1/6
(16.6%) exhibited a diffuse pattern of immunoreactivity
(Figure 4) while the remaining 5/6 (83.3%) had a focal
staining pattern (Figure 5b and Table I).
Adenocarcinomas Nuclear p53 staining was exhibited by
33/53 (62.3%) adenocarcinomas and a variety of staining
patterns were found. Of the carcinomas which were
immunopositive, 22/33 (66.7%) had a diffuse pattern of p53
staining (Figure Sa), 5/33 (15.1%) had a focal pattern and
6/33 (18.2%) had a scattered immunostaining distribution
(Figure Sc). No relationship was found between p53 staining
and histological stage of differentiation, Dukes' stage or site
within the colon.
Figure 4 Peroxidase staining of p53 protein in a tubullovillous
adenoma. The nuclei of the adenomatous epithelial cells (upper
left) have intense p53 immunoreactivity, whereas the adjacent
normal epithelial cells (lower right) are p53 negative (x 125).
Dual staining of tissues for bcl-2 and p53 immunoreactivity
Recent work has suggested that wild-type p53 oncoprotein
down-regulates the expression of bcl-2 (Miyashita et al.,
1994a, b). A total of 5/19 (26.3%) of adenomas and 12/53
(22.6%) of adenocarcinomas contained areas of both bcl-2
and p53 immunoreactivity. This suggested that these samples
contained cells which express both bcl-2 and p53. To
investigate this possibility we carried out dual staining for
both bcl-2 and p53. In the majority of specimens which were
immunopositive for both bcl-2 and p53, the areas of
immunoreactivity for these two proteins were topographically
distinct. Only in 1/19 adenomas and 2/53 carcinomas did
identical cells express both bcl-2 and p53 (Figure 6c). This was
an uncommon finding with the great majority of epithelial
cells within these three neoplasms expressing either p53 or bcl-
2 alone (Figure 6). Even in areas in which the cells were
immunopositive for both bcl-2 and p53 there was evidence of
reciprocity of their expression. As shown in Figure 6, a few
cells stained positive for both bcl-2 and p53. However, the cells
with the most intense bcl-2 immunoreactivity stained either
weakly or were entirely negative for p53 and vice versa (see
cells indicated by small arrows in Figure 6).
Discussion
In this study we find a lower proportion of carcinomas
(36.5%) than adenomas (63.2%) express bcl-2 protein.
Similar results have been reported (Ofner et al., 1995;
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Figure 5 Peroxidase staining of p53 protein of the same
neoplasms as in Figure 2. Two well-differentiated adenocarcino-
mas, Dukes' stage B (a) and Dukes' stage A (c), and a
tubullovillous adenoma (b). In a the same area as in Figure 2a
is shown in which the nuclei stain positive for p53. Focal (b) and
scattered (c) patterns of p53 staining are also illustrated ( x 370).
Sinicrope et al., 1995) though the reduction in bcl-2
expression in carcinomas compared with adenomas is less
dramatic than in our series. Two other studies (Bronner et
al., 1995; Hague et al., 1994) report that more than 90% of
adenomas express bcl-2 and they find no reduction in the
proportion of carcinomas expressing bcl-2. The reasons for
these discrepancies are unclear though they may be related to
methodological differences or to the small sample sizes of
these studies. However, the lower rate of bcl-2-positive
carcinomas in our series in unlikely to be due to false-
negative reporting since there was intense bcl-2 immuno-
reactivity in lymphocytes in all specimens studied (Figure 2b,
insert).
The immunostaining was always confined to the cytoplasm
and nuclear membrane as has been previously reported
(Merritt et al., 1995; Sinicrope et al., 1995). A striking feature
was the focal nature of bcl-2 immunoreactivity in the
majority of tumours (84.2%) studied. This is unlikely to be
due to lack of reproducibility of bcl-2 immunoreactivity
within epithelial cells as the staining of lymphocytes was
constant within sections. Nor is it likely that the hetero-
geneity of bcl-2 expression within the cytoplasm can be
explained by differences in the position of cells within the cell
cycle (Lu et al., 1994). Differences in the local cellular
environment may explain the heterogeneity of bcl-2 expres-
sion such as variation of growth factor concentration or
lymphocytic infiltration (Ofner et al., 1995). However, little is
known about extracellular signals capable of regulating bcl-2
expression.
The cause of bcl-2 expression in adenomas and in
morphologically normal crypts adjacent to cancers is
unclear. The simplest explanation is that the clone of cells
which has developed into the adenoma is derived from a cell
at the base of the crypt and the bcl-2 expression which is
normal for these crypt base stem cells has been retained.
However, there is no evidence to indicate which cells along
the crypt/villus axis actually develop into malignant clones,
though experiments in mice carrying a truncated Apc gene
suggest they may arise from the lower proliferative zone of
the crypt (Oshima et al., 1995). Other possible explanations
include translocation of the bcl-2 gene to another chromo-
somal site such as the t(14:18) translocation in non-Hodgkin's
B-cell lymphomas; this places bcl-2 in close proximity to
powerful enhancer elements in the Ig heavy chain locus
(Korsmeyer, 1992). Alternatively, mutation of the bcl-2
promoter causing deregulated protein expression or muta-
tion of the bcl-2 protein itself, thereby increasing its half-life,
are other possible mechanisms. However, there is no
information on the incidence of bcl-2 translocations or
mutations in human colorectal cancer, though a single
mutation of uncertain physiological significance has been
detected in a human colorectal cancer cell line (Pietenpol et
al., 1994). Another mechanism is that loss of wild-type,
functional p53 could lead to deregulated expression of bcl-2
protein. The bcl-2 gene is transcriptionally repressed by p53 a
and loss of p53 is sufficient to up-regulate bcl-2 (Miyashita,
1994a and b). However, such a mechanism is unlikely to
account for the expression of bcl-2 in many of the adenomas
since mutation and loss of heterozygosity of p53 occurs
typically at the transition between adenoma and carcinoma
(Baker et al., 1990). Our observation of the high rate of bcl-2
positive adenomas and its more extensive expression in
histologically normal crypts in regions adjacent to adenomas
suggests that bcl-2 expression is an early event in adenoma
formation and occurs before changes in p53. Interestingly, we
Figure 6 AEC staining for Bcl-2 protein (red) and 3,3'dia-
minobenzidine + nickel chloride staining of p53 protein (blue-
black) of a rectal tubullovillous adenoma. Cells that stain positive
for Bcl-2 stain weakly or are entirely negative for p53 (small
arrows). Occasional cells that stain for both Bcl-2 and p53 are
shown (c, large-headed arrow). a and b, x 275; c, x 500.
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obsenred that bcl-2 immunoreactivitv w-as more intense
adjacent to Peyer's patches. This raises the possibility that
epigenetic factors such as secreted cellular products may
influence bcl-2 expression. Alternatively, changes in extra-
cellular matrix, that we have recently shown to regulate bcl-2
expression. may be important (Dive et al.. 1995).
There are a number of reasons why bcl-2 expression may
be lost during the evolution of colorectal cancer. In the
present study w-e demonstrate a clear inverse relationship
between bcl-2 and p53 expression in both adenomas and
carcinomas, confirming our previous preliminary observa-
tions (Merritt et al.. 1995). Although 26% of adenomas and
20% of cancers contained areas of bcl-2 and p53
immunoreactivitv. double staining demonstrated that only
50/ of the adenomas and 4% of the carcinomas contained
cells which actually expressed both proteins. Even in the
uncommon instances where cells did express both proteins
there was evidence of reciprocity of bcl-2 and p53 expression
in the majority of cells (Figure 6). These results are in
accordance with previous data demonstrating that wild-type
p53 (Selvakumaran et al.. 1994) and some p53 mutants (mut
175) (Haldar et al.. 1994) down-regulate bcl-2 by binding to a
transcriptional silencer element within the bcl-2 promoter
(Miyashita et al.. 1994a). Although the p53 antibody used in
this studv could detect both stabilised Wild-type and most p53
mutants, it is likely that the majority. but not necessarily all.
of the p53 immunoreactivity reflected mutant rather than
wild-type p53 (Baker et al.. 1990: Hall and Lane. 1994). This
suggests that either most p53 mutants can transcriptionallv
repress bcl-2. which is unlikely, or other mechanisms account
for the loss of bcl-2 expression. For example. there might be
loss of heterozygosity of the bcl-2 gene. together with
mutation and inactiv-ation of the other allele. The bcl-2 gene
locus is on chromosome segment 18q21.3 (Tsujimoto t a!..
1985). Loss of chromosome 18q occurs in 69% of colorectal
cancer (Jen et al.. 1994) and allelic loss of the bcl-2 gene locus
has been observed in 60%/o of colorectal cancers (Ay-han et al..
1994). Alternatively. high levels of bcl-2 may not be required
to prevent apoptosis when tumours acquire p53 mutations
and other survival factors come into play.
Both p53 and bcl-2 regulate radiation-induced apoptosis in
colorectal epithelium (Merritt et al.. 1994. 1995). Studies on
mouse lymphocytes indicate that bcl-2 is able to suppress the
p53-mediated apoptosis induced by DNA damage (Manrn et
al.. 1994). This raises the possibility that knowledge of bcl-2
status might provide information predicting the response of
colorectal tumours to radio- and chemotherapy and patient
survival. Recent results suggest that bcl-2 expression is an
independent prognostic factor associated with favourable
clinical outcome (Ofner et al.. 1995). suggesting that loss of
bcl-2 expression is associated with either the development of
other more potent survival factors or alternatively loss of
pro-apoptotic genes such as bax (Oltvai et al.. 1993) or bak
(Farrow et al.. 1995).
In summary. we have demonstrated that bcl-2 is expressed
in a high proportion of adenomas but is often lost during
progression to carcinoma and we have shown an inverse
relationship between bcl-2 and p53 expression in cells of both
colorectal adenomas and carcinomas. Further studies of
other regulators of apoptosis are required before either the
ability of colorectal tumours to undergo apoptosis can be
predicted or the value of p53 or bcl-' as prognostic indicators
is established.
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